176 related articles for article (PubMed ID: 18394019)
1. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib-induced thyrotoxicosis - a not so rare entity.
Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
[TBL] [Abstract][Full Text] [Related]
3. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
[TBL] [Abstract][Full Text] [Related]
4. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
Daniels GH
Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
[No Abstract] [Full Text] [Related]
5. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
Sakurai K; Fukazawa H; Arihara Z; Yoshida K
Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
9. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
Alexandrescu DT; Popoveniuc G; Farzanmehr H; Dasanu CA; Dawson N; Wartofsky L
Thyroid; 2008 Jul; 18(7):809-12. PubMed ID: 18631016
[No Abstract] [Full Text] [Related]
12. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
13. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
15. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Sella A; Hercbergs AH; Hanovich E; Kovel S
Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
[TBL] [Abstract][Full Text] [Related]
16. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
17. Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report.
Babacan T; Sevinc A; Akarsu E; Balakan O
Chemotherapy; 2012; 58(2):142-5. PubMed ID: 22584361
[TBL] [Abstract][Full Text] [Related]
18. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
[TBL] [Abstract][Full Text] [Related]
19. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.
Faris JE; Moore AF; Daniels GH
Thyroid; 2007 Nov; 17(11):1147-9. PubMed ID: 17714037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
